The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Questcor Reports Fourth Quarter and Full Year 2011 Financial Results

Wednesday, February 22, 2012

Questcor Reports Fourth Quarter and Full Year 2011 Financial Results16:01 EST Wednesday, February 22, 2012-Q4 2011 Net Sales of $75.5M vs. $29.3M in Q4 2010- -Q4 2011 Net Income per Diluted Share of $0.48 vs. $0.10 in Q4 2010- -2011 Net Sales of $218.2 Million vs. $115.1M in 2010- -2011 Net Income per Diluted Share of $1.21 vs. $0.54 in 2010- -Conference Call and Webcast to Be Held Today at 4:30 p.m. ET, 1:30 p.m. PT-ANAHEIM, Calif., Feb. 22, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2011.  Net sales for the fourth quarter were $75.5 million, reflecting continued physician acceptance of H.P. Acthar® Gel (Acthar) for treating serious, difficult-to-treat medical conditions.  Net sales in the fourth quarter 2010 were $29.3 million.GAAP net income for the fourth quarter of 2011 was $31.6 million or $0.48 per diluted common share.  GAAP net income for the fourth quarter of 2010 was $6.4 million, or $0.10 per diluted common share.  Non-GAAP net income (which excludes non-cash share-based compensation expense, depreciation and amortization expense, tax adjustments and a goodwill impairment charge) for the quarter ended December 31, 2011 was $31.6 million or $0.47 per diluted common share.  Non-GAAP net income for the year ago quarter was $8.0 million, or $0.12 per diluted common share.For the year ended December 31, 2011, net sales totaled $218.2 million, compared to $115.1 million in the prior year.  GAAP net income for the year ended December 31, 2011 was $79.6 million or $1.21 per diluted share, compared to GAAP net income of $35.1 million or $0.54 per diluted share for the year ended December 31, 2010.  Non-GAAP net income was $84.0 million or $1.27 per diluted share for the year ended December 31, 2011, compared to non-GAAP net income of $39.0 million or $0.60 per diluted share for the year ended December 31, 2010."Net sales growth in the fourth quarter was driven by the increasing numbers of physicians who are recognizing the potential for Acthar to help patients with MS and NS," said Don M. Bailey, President and CEO of Questcor.  "We are particularly encouraged by the growing number of physicians who recognize the therapeutic value of Acthar in their practices, especially for those patients who have not adequately responded to other treatments.  At the same time, we are continuing to build our understanding of the potential immune-modulating properties of Acthar, and are considering how best to study the broader possible therapeutic applications in other inflammatory and autoimmune diseases, many of which are already in the list of approved indications on the Acthar label."  "The planned expansion of our nephrology sales force from 28 to 58 representatives is underway and should be completed during the second quarter, ahead of our original schedule," noted Steve Cartt, Chief Operating Officer. "We are also planning to increase the number of neurology representatives after the nephrology expansion is complete. Furthermore, a possible pilot commercial effort in rheumatology is being carefully considered for the fourth quarter of this year.""Paid prescriptions in IS were higher in the fourth quarter, reflecting a growing recognition of the important role of Acthar in treating this devastating condition. As announced yesterday, we were pleased to accept the award from the Child Neurology Foundation (CNF) for outstanding corporate responsibility and leadership, and have further increased our funding to CNF so that they can continue their important research and education efforts related to childhood neurological conditions like IS," added Mr. Cartt."Our scientific research and investments continue to expand. In addition to our ongoing studies in NS and MS, we are planning new efforts in Lupus, Diabetic Nephropathy and other auto-immune and inflammatory conditions with unmet medical need," commented Dr. David Young, Chief Scientific Officer. "We have also increased our investigation into better understanding how Acthar works and how its biological activity differs from that of corticosteriods such as methylprednisolone and prednisone."The Company continues to invest in its management systems and infrastructure, including those related to scientific research, medical affairs, and compliance.  Last week, Questcor announced the appointment of Scott Whitcup, M.D., Chief Scientific Officer of Allergan, Inc., to Questcor's Board of Directors. Also, the Company has recently promoted:-Steve Cartt to Chief Operating Officer-Dave Medeiros to Executive Vice President and Chief Technical Officer-Eldon Mayer to Senior Vice President of Commercial Operations-Ray Furey to Vice President, Compliance and Chief Compliance Officer-Gary Hogge, PhD, to Vice President, Medical Affairs.In addition, Questcor has recently hired Darlene Romine as Vice President, Sales Operations."These promotions and additions reflect the expanded needs of Questcor as our sales and headcount have grown and are expected to continue to increase," noted Don Bailey. "I want to congratulate all of these executives on their well-deserved promotions."Acthar Label InformationThe label for Acthar was modernized in October 2010 and has 19 approved indications.  Substantially all of the Company's net sales result from prescriptions written by physicians for the following on-label indications for Acthar:Multiple Sclerosis (MS): "for the treatment of acute exacerbations of multiple sclerosis in adults.  Clinical controlled trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis.  However, there is no evidence that it affects the ultimate outcome or natural history of the disease." Typically Acthar is used as second line treatment for patients with MS exacerbations. Nephrotic Syndrome (NS): "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  NS can result from several underlying conditions, and prescribing physicians indicate that Acthar is most commonly being used in patients who suffer from NS due to idiopathic membranous nephropathy, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, minimal change disease and lupus. Infantile Spasms (IS): "as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age." The Company is currently planning to explore the potential initiation of a commercial effort in rheumatology in late 2012, as Acthar is approved for the following rheumatology-related conditions: Collagen Diseases: "during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)."Rheumatic Disorders: "as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis."Shipped Acthar Vial and Prescription Trend InformationDuring the fourth quarter of 2011, Questcor shipped 3,360 vials of Acthar, compared to 1,680 vials in the year ago quarter.  For the full year of 2011, Questcor shipped 10,710 vials of Acthar compared to 6,696 vials in 2010.  The Company's quarterly vial shipments continue to be subject to significant variation due to the size and timing of individual orders received from Questcor's distributor, and the timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter.  Fourth quarter-ending inventory levels in the channel appear to have remained relatively unchanged compared to the levels at the end of the third quarter of 2011. The Company believes that investors should consider the Company's results over several quarters when analyzing the Company's performance.  Because Acthar prescriptions are filled at specialty pharmacies, the Company does not receive complete information regarding either the number of prescriptions or the number of vials by therapeutic area for all of the patients being treated with Acthar.  However, Questcor is able to monitor trends in payer mix and areas of therapeutic use for new Acthar prescriptions based on data it receives from its reimbursement support center. Questcor estimates that over 90% of new Acthar prescriptions are processed by this support center, but believes that very few refill prescriptions are processed there. In an effort to help investors better understand historical trends in the prescriptions written for Acthar within each of its current three key therapeutic areas, MS, NS, and IS, Questcor has grouped prescriptions processed by its reimbursement center into two groups -- "Paid" and "Fully Rebated." "Paid" prescriptions include those prescriptions for which Questcor retains its full selling price for Acthar, as well as Tricare prescriptions that subject Questcor to a rebate obligation of up to 24% of its selling price.  "Fully Rebated" prescriptions are those for which Questcor can identify that it has recorded a rebate liability approximately equal to (or for periods prior to January 1, 2010 greater than) Questcor's selling price.  From time to time during the past several years, the rebate liability for some government insurance programs has shifted between these two categories. Therefore, the prescriptions that fall into the "Paid" and "Fully Rebated" categories have also shifted over time as follows: "Paid" prescriptions (Rxs) include all prescriptions in the following payer categories: Commercial--For all time periods.Tricare--For 2010 and 2011, but not 2009.Medicaid Managed Care--For all time periods through March 22, 2010 (see Note 1 below the tables)."Fully Rebated" prescriptions (Rxs) include: Those reimbursed by fee-for-service Medicaid insurance and other state programs eligible for full rebates as Medicaid Waivers Programs for all time periods. Tricare--For 2009.Medicaid Managed Care--For all time periods beginning March 23, 2010 (see Note 1 below the tables). The following tables show, for each of the three key Acthar therapeutic uses, the number of new prescriptions shipped grouped into "Paid" and "Fully Rebated": Multiple Sclerosis (and related conditions) New RxsPaidYear-Over-YearGrowth in Paid RxFully RebatedTotal2009   Q1-09 78225%886   Q2-09 124254%17141   Q3-09 141176%20161   Q4-09 213209%15228   Total 2009 556211%606162010   Q1-10231196%12243   Q2-10304145%24328   Q3-10323129%19342   Q4-1035466%24378   Total 2010 1,212118%791,2912011   Q1-11508120%49557   Q2-11751147%58809   Q3-11886174%46932   Q4-11945167%44989Total 20113,090155%1973,287Nephrotic Syndrome (and related conditions) New Rxs *PaidFully RebatedTotal2010   Q1-1011011   Q2-10415   Q3-10808   Q4-10707   Total 2010 301312011   Q1-1118119   Q2-1145449   Q3-1160262   Q4-1114619165Total 201126926295* Questcor commenced commercial efforts in NS in the second quarter of 2011.Infantile Spasms (and related conditions) New Rxs**PaidFully RebatedTotal2009   Q1-0910475179   Q2-09 9168159   Q3-096058118   Q4-099445139   Total 20093492465952010   Q1-108948137   Q2-109566161   Q3-109278170   Q4-109168159   Total 2010 3672606272011   Q1-118971160   Q2-1110679185   Q3-1111269181   Q4-1112051171Total 2011427270697** Questcor commenced commercial efforts in IS in the fourth quarter of 2010.Notes:(1) Because the March 2010 health care legislation made Medicaid Managed Care Organization (MCO) prescriptions rebate eligible effective March 23, 2010, a rebate liability for the MCO prescriptions estimated to be filled on or after March 23, 2010 has been accrued. The Company does not have the ability to accurately identify every Medicaid Managed Care prescription so it is possible that some prescriptions identified as "Paid" in the tables may subsequently be reclassified as "Fully Rebated."(2) "Related Conditions" includes diagnoses that are either alternate descriptions of the medical condition or are closely related to the medical condition which is the focus of the table. For example, a prescription for "demyelinating disease of the central nervous system" would be included as an MS-related condition for purpose of this table. About 5% of the prescriptions in the tables are for related conditions.(3) A prescription may or may not represent a new patient or a new therapy for the patient receiving the prescription.  This can more frequently be the case for NS prescriptions due to the longer treatment regimen for NS.  Questcor uses business rules to determine whether a prescription should be included in this table. From time to time the Company may modify these rules which could cause some changes to the historic numbers in the tables above.(4) Historical trend information is not necessarily indicative of future results. Additionally, paid prescriptions should not be viewed as predictive of Questcor's net sales due to a variety of factors, including changes in the number of vials used in connection with each prescription.Cash and Share Repurchase Program As of February 15, 2012, Questcor's cash, cash equivalents and short-term investments totaled $226 million, and its accounts receivable totaled $44 million. The Company did not repurchase any shares during the fourth quarter.  As of December 31, 2011, Questcor had 63.6 million shares of common stock outstanding, with 4.3 million shares remaining under its common stock repurchase program.Sales ReservesQuestcor's sales reserves during the quarter ended December 31, 2011, including the Company's reserves for Medicaid rebates, represented 12% of gross sales of $86.1 million.As required by federal regulations, Questcor provides rebates to state Medicaid programs for Acthar dispensed to Medicaid patients covered under Medicaid rebate-eligible insurance plans.  Since the Company does not receive rebate claims from the various state Medicaid agencies until well after the close of the quarter in which the underlying sales of vials to its distributor took place, the Company establishes reserves for expected rebate claims on a quarterly basis.  As a result of the adoption of health care reform, for periods after March 23, 2010, the Company has also included in this reserve an estimate for the liability due to states related to prescriptions of Acthar for patients covered under state Medicaid Managed Care Organizations (Medicaid MCO), which prescriptions were not previously rebate eligible.Questcor experienced a decrease in sales reserves as a percentage of gross sales during each of the four quarters of 2011. The principal reasons for these decreases have been (1) an increase in the percentage of total Acthar prescriptions written to treat adults suffering from MS and NS relative to the percentage used to treat infants suffering from IS, as there is a very high percentage of infants enrolled in Medicaid, and (2) an increase in the number of IS prescriptions being fulfilled through the Acthar free drug program administered by the National Organization for Rare Disorders.  Since September 2007, Questcor has provided $124 million in value through this free drug program.Conference Call Details The Company will host a conference call and slide presentation via webcast today, February 22, 2012, at 4:30 p.m. ET/ 1:30 p.m. PT, to discuss fourth quarter and full year 2011 results.  Don Bailey, President and Chief Executive Officer, and other members of the management team will host the call. To participate in the live call by telephone, please dial (877) 941-0844 for domestic participants and (480) 629-9835 for international participants.  Participants are asked to call the above numbers 5-10 minutes prior to the start time.  A listen-only webcast of the conference call including the presentation slides will be accessible in the "Investor Relations" section under "Events & Presentations" at  If listening via telephone, to view the accompanying presentation slides, navigate to the live webcast as noted above and choose the "No Audio ? Slides Only" option to view the slides in conjunction with the live conference call.  Listeners should go to the website at least 15 minutes prior to the live conference call to install any necessary software.An audio replay of the call will be available for 7 days following the call.  This replay can be accessed by dialing (800) 406-7325 for domestic callers and (303) 590-3030 for international callers, both using passcode 4509827#.  An archived webcast will also be available at of Non-GAAP Net Income The Company believes it is important to share non-GAAP financial metrics with shareholders as these metrics may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the Company's financial performance is enhanced as a result of our disclosing these non-GAAP financial metrics. Non-GAAP net income should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP net income.  The reconciliation between GAAP and Non-GAAP net income is provided with the financial tables included with this release.About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Questcor currently generates substantially all of its net sales from: the treatment of patients with acute exacerbations of multiple sclerosis in adults, the treatment of patients with nephrotic syndrome, and the treatment of patients with infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, and Dermatomyositis (Polymyositis).  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information about Questcor, please visit Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: Our reliance on Acthar for substantially all of our net sales and profits;Reductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations; The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions;The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;Research and development risks, including risks associated with Questcor's work in the area of NS and potential work in the area of Lupus, and our reliance on third-parties to conduct research and development and the ability of research and development to generate successful results;Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;Our ability to receive high reimbursement levels from third party payers;An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients  and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results;Our ability to effectively manage our growth, including the expansion of our NS selling effort, and our reliance on key personnel;The impact to our business caused by economic conditions;Our ability to protect our proprietary rights;The risk of product liability lawsuits;Unforeseen business interruptions and security breaches;Volatility in Questcor's monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; andOther risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC.The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance. Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.For more information, please visit or Pharmaceuticals, Inc.Consolidated Statements of Income(In thousands, except per share amounts)Three Months EndedDecember 31,Twelve Months EndedDecember 31,2011201020112010RevenueNet sales$75,535$  29,296$  218,169$115,131         Cost of sales (exclusive of amortization of purchased technology)4,0131,72312,4598,013Gross profit71,52227,573205,710107,118Operating expenses:              Selling and marketing16,99811,16356,72831,519              General and administrative5,7662,39317,74310,279              Research and development5,7303,06616,77810,934              Depreciation and amortization2921541,044546              Impairment of goodwill--299-Total operating expenses28,78616,77692,59253,278Income from operations42,73610,797113,11853,840Interest and other income, net145147627533Income before income taxes42,88110,944113,74554,373Income tax expense11,2404,52734,15419,302Net income$ 31,641$  6,417$79,591$  35,071Net income per share:Basic$  0.50$  0.10$  1.27$  0.56Diluted$  0.48$  0.10$  1.21$  0.54Shares used in computing net income per share:Basic63,23662,25262,49862,112Diluted66,56565,39066,01064,741Reconciliation of Non-GAAP Adjusted Financial DisclosureAdjusted net income $31,584$8,021$83,956$38,988Share-based compensation expense (1)(1,416)(598)(5,128)(2,649)Depreciation and amortization expense (2)(216)(90)(731)(352)Tax adjustments (3)1,689(916)1,703(916)Impairment of goodwill (4)--(209)-Net income ? GAAP$  31,641$6,417$79,591$35,071Adjusted net income per share ? basic$  0.50$  0.13$  1.34$  0.63Share-based compensation expense (1)(0.02)(0.01)(0.08)(0.04)Depreciation and amortization expense (2)(0.00)(0.00)(0.01)(0.01)Tax adjustments (3)0.03(0.01)0.03(0.01)Impairment of goodwill (4)(0.00)(0.00)(0.00)(0.00)Net income per share ? basic$  0.50$  0.10$  1.27$  0.56Adjusted net income per share ? diluted$  0.47$  0.12$  1.27$  0.60Share-based compensation expense (1)(0.02)(0.01)(0.08)(0.04)Depreciation and amortization expense (2)(0.00)(0.00)(0.01)(0.01)Tax adjustments (3)0.03(0.01)0.03(0.01)Impairment of goodwill (4)(0.00)(0.00)(0.00)(0.00)Net income per share ? diluted$  0.48$  0.10$  1.21$  0.54Net income per share ? basic and diluted may not foot due to rounding. Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income: (1)Share-based compensation expense.(2)Depreciation and amortization expense(3)Tax adjustments include: (1) the valuation allowance we established in the fourth quarter of 2010 relating to our single sales factor apportionment election which was made in 2011 for California; (2) the recording of a one-time tax credit in 2011 for the orphan drug designation; and (3) the reserve for the liability associated with the Ohio Commercial Activity Tax for the period 2007 ? 2010 (the expense associated with this reserve is included in operating expenses).(4)Impairment of goodwill related to the write-off of goodwill associated with an acquisition transaction completed in 1999. Questcor Pharmaceuticals, Inc.Consolidated Balance Sheets(In thousands, except share amounts)December 31,2011 December 31,2010  ASSETSCurrent assets:Cash and cash equivalents$           88,469$  41,508Short-term investments121,68073,324Total cash, cash equivalents and short-term investments210,149114,832Accounts receivable, net of allowances of $0 and $25 at December 31, 2011 and 2010, respectively27,80111,128Inventories, net of allowances of $0 and $158 at December 31, 2011 and 2010, respectively5,2263,726Prepaid income taxes6,9403,532Prepaid expenses and other current assets3,3911,864Deferred tax assets12,0938,417Total current assets265,600143,499Property and equipment, net1,970872Purchased technology, net2,7783,074Goodwill-299Deposits and other assets5665Deferred tax assets5,4044,184Total assets$  275,808$  151,993LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable$  5,503$  3,869Accrued compensation11,5904,158Sales-related reserves34,11921,511Other accrued liabilities4,5091,973Total current liabilities55,72131,511Lease termination, deferred rent and other non-current liabilities261355Total liabilities55,98231,866Shareholders' equity:Preferred stock, no par value, 7,500,000 shares authorized; none outstanding--Common stock, no par value, 105,000,000 shares authorized, 63,645,781 and 62,418,464 shares issued and outstanding at December 31, 2011 and 2010, respectively94,97674,809Retained earnings124,88645,295Accumulated other comprehensive income(36)23Total shareholders' equity219,826120,127Total liabilities and shareholders' equity$  275,808$  151,993Questcor Pharmaceuticals, Inc.Consolidated Statements of Cash Flows(In thousands)Year EndedDecember 31,20112010OPERATING ACTIVITIESNet income$  79,591$  35,071Adjustments to reconcile net income to net cash provided by operating activities:Share-based compensation expense7,3263,739Deferred income taxes(4,896)(1,029)Amortization of investments1,250678Depreciation and amortization1,044546Impairment of goodwill299-Loss on disposal of property and equipment11-Changes in operating assets and liabilities:Accounts receivable(16,673)3,705Inventories(1,500)(348)Prepaid income taxes(3,408)(3,532)Prepaid expenses and other current assets(1,527)(702)Accounts payable1,634(9,052)Accrued compensation7,4322,018Sales-related reserves12,6086,589Other accrued liabilities2,526(255)Other non-current liabilities(118)(871)Net cash flows provided by operating activities85,59936,557INVESTING ACTIVITIESPurchase of property and equipment(1,823)(713  )Purchase of short-term investments(162,301)(106,647)Proceeds from maturities of short-term investments112,63662,560Deposits and other assets9645Net cash flows used in investing activities(51,479)(44,155)FINANCING ACTIVITIESIncome tax benefit realized from share-based compensation plans17,7121,335Issuance of common stock, net6,5821,942Repurchase of common stock(11,453)-Net cash flows provided by financing activities12,8413,277Increase (decrease) in cash and cash equivalents46,961(4,321)Cash and cash equivalents at beginning of period41,50845,829Cash and cash equivalents at end of period$  88,469$  41,508Supplemental Disclosures of Cash Flow Information:Cash paid for interest$          16$           7Cash paid for income taxes$   25,278$  23,185Supplemental Disclosures of Non-Cash Investing and Financing Activities:Capital lease obligation$          34$           -SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey, +1-714-786-4210 of Questcor Pharmaceuticals, Inc.; or Investors, Greg Gin or Doug Sherk, both at +1-415-896-6820; or Media, Janine McCargo, +1-646-688-0425, all for Questcor Pharmaceuticals, Inc.